Purinergic signaling: decoding its role in COVID-19 pathogenesis and promising treatment strategies

被引:0
作者
Zahra Shafaghat
Amir-Hossein Khosrozadeh Ghomi
Hossein Khorramdelazad
Elaheh Safari
机构
[1] Iran University of Medical Sciences,Department of Immunology, School of Medicine
[2] Rafsanjan University of Medical Sciences,Department of Immunology, School of Medicine
来源
Inflammopharmacology | 2023年 / 31卷
关键词
COVID-19; Purinergic signaling; CD73; CD39; Targeted therapy;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:3005 / 3020
页数:15
相关论文
共 495 条
  • [1] Abbasifard M(2020)The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics Life Sci 257 866-875
  • [2] Khorramdelazad H(2021)Potential therapeutic benefits of dipyridamole in COVID-19 patients Curr Pharm Des 27 419-426
  • [3] Aliter KF(2021)Platelet function in viral immunity and SARS-CoV-2 infection Semin Thromb Hemost 47 611-629
  • [4] Al-Horani RA(2020)The adenosine pathway in immuno-oncology Nat Rev Clin Oncol 17 31-39
  • [5] Allaoui A(2019)Targeting the CD73-adenosine axis in immuno-oncology Immunol Lett 205 355-367
  • [6] Khawaja AA(2013)CD39 and CD73 in immunity and inflammation Trends Mol Med 19 175-177
  • [7] Badad O(2020)Subacute stent thrombosis in a patient with COVID-19 pneumonia Proc (bayl Univ Med Cent) 34 277-284
  • [8] Naciri M(2013)Unanticipated parallels in architecture and mechanism between ATP-gated P2X receptors and acid sensing ion channels Curr Opin Struct Biol 23 99-109
  • [9] Lordkipanidzé M(2021)CD39 and CD73 as promising therapeutic targets: what could be the limitations? Front Pharmacol 12 238-247
  • [10] Guessous F(2009)Pyroptosis: host cell death and inflammation Nat Rev Microbiol 7 2792-2807